Is Vyzulta Approved for Open-Angle Glaucoma?
Yes, Vyzulta (latanoprostene bunod ophthalmic solution 0.024%) is FDA-approved to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.[1][2]
How Does Vyzulta Work for Glaucoma?
Vyzulta is a prostaglandin analog that lowers IOP by increasing aqueous humor outflow through both trabecular and uveoscleral pathways. Clinical trials showed it reduces IOP by 7-9 mmHg on average in open-angle glaucoma patients, comparable to latanoprost but with potentially better 24-hour control.[2][3]
Who Can Use It and When?
It's indicated for adults with open-angle glaucoma or ocular hypertension. Use one drop in the affected eye(s) daily in the evening. Not for children under 16 or acute angle-closure glaucoma. Contact lenses should be removed before dosing.[1][4]
Common Side Effects Patients Report
Eye redness (conjunctival hyperemia) occurs in up to 50% of users initially but often fades. Other effects include eyelash growth, iris darkening, and blurred vision. Serious risks like macular edema are rare (less than 2%).[1][2]
How Does It Compare to Latanoprost (Xalatan)?
Both are prostaglandins for open-angle glaucoma, but Vyzulta's bunod metabolite may enhance outflow. Studies show similar efficacy, though Vyzulta has higher hyperemia rates early on.[3][5]
Generic or Patent Status?
Vyzulta launched in 2018. Patents expire around 2030, with no generics approved yet. Check DrugPatentWatch.com for litigation updates and exact expiry dates.[6]
[1] FDA Label: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208818s000lbl.pdf
[2] Bausch + Lomb Prescribing Info: https://www.vyzulta.com
[3] Weinreb et al., Am J Ophthalmol (2016): https://pubmed.ncbi.nlm.nih.gov/27184559/
[4] American Academy of Ophthalmology: https://www.aao.org/eye-health/drugs/vyzulta
[5] Medscape Comparison: https://reference.medscape.com/drug/vyzulta-latanoprostene-bunod-4000164
[6] DrugPatentWatch.com: https://www.drugpatentwatch.com/p/tradename/VYZULTA